In the Fight Against Prostate Cancer Information is the Most Powerful Tool.

Promise.

A collaboration between:

Advancing Cancer Treatment

The Prostate Cancer Clinical Trials Consortium
PROMISE Registry:
A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
What is the PROMISE Registry?

• Channing Paller, MD (Johns Hopkins) and Heather Cheng, MD, PhD (UW/Fred Hutch) have partnered with Advancing Cancer Treatment and the PCCTC to develop a prospective registry study that will explore germline mutations and associated outcomes in men with prostate cancer.

• Participants will receive clinical-grade germline cancer risk testing and genetic counseling at no cost as part of the study screening process.

• Eligible participants will be followed long-term and receive periodic newsletters to help connect them with new trials and treatments targeted to their specific genetic mutations.

• The PROMISE Registry is a virtual study – everything happens online & participants don’t have to leave their current provider.
Why the PROMISE Registry?

- Timely with FDA’s approval of Rucaparib and Olaparib
  - More testing for PARPi/clinical trial candidacy will be necessary
  - Post-PARPi patients will be coming, some with rare gene variants
  - Rare germline mutations will necessitate working together to gather strongest data and assess the best treatments for this subset of patients

- PROMISE is available nationwide - inviting community and academic partners to engage

- Due to PROMISE’s virtual nature, patients don’t need to leave their current provider to participate

- Long term >10 year investment to registry and patients

- For patients AND providers, knowledge is power
PROMISE Study Objectives

Primary Objective:
• Recruit a prospective registry of men with all stages of prostate cancer with germline cancer risk pathogenic variants — *ATM, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53* — using public education programs, outreach, and no-cost germline cancer risk testing

Secondary Objectives:
• Assess the frequency of pathogenic germline variants in men with prostate cancer
• Identify and recruit a control group of patients with variants of uncertain significance (VUS) in their clinical or research results in the following genes - *ATM, ATR, BRCA1, BRCA2, FAM175A, GEN1, HOXB13, MRE11A, PALB2 and XRCC2*
Secondary Objectives, continued:
• Collect data on disease characteristics and examine the association between disease characteristics and P/LP germline variants and VUS of interest
• Collect patient-reported outcome (PRO) measures associated with genetic testing
• Collect longitudinal outcome data including significant medical events and overall survival

Exploratory Objectives:
• Capture family history to assist with interpretation of germline genetic testing results
• Provide a mechanism to notify men with specific P/LP germline variants about current and future clinical trials and research opportunities
• Provide subjects with updated information about new research results, ongoing clinical trial opportunities, and treatments approved by the Food and Drug Administration (FDA)
Accrual Target & Eligibility

Anticipated accrual:
• Approximately 5000 men with prostate cancer will be screened to identify:
  • 400 men with germline pathogenic and likely pathogenic variants
  • 100 men with germline variants of uncertain significance

Eligibility:
• Participants must be US residents, age 18+, with documented prostate cancer (by tissue biopsy, PSA > 100 ng/dL, or imaging)

Any Sub-Population:
• Localized
• nmHSPC (BCR)
• mHSPC
• nmCRPC
• mCRPC

Any Histology:
• Adenocarcinoma
• Neuroendocrine
• Cribriform/Intraductal
• Small cell carcinoma
• Ductal carcinoma
Patient Recruitment

PROMISE will employ various recruitment methods, including:
• Recommendation to patients by their doctors, genetic counselors, or other care providers
• Community outreach including patient advocacy and support groups
• Direct-to-patient marketing via social and traditional media
• Within the Prostate Cancer Clinical Trials Consortium network of 100 hospitals, practices and academic research centers

PROMISE is committed to recruiting a diverse patient population by providing new & equitable opportunities for patients & providers that do not have routine access to germline testing due to logistical or financial considerations
The PROMISE Team

Principal Investigators

Channing Paller, MD
Heather Cheng, MD, PhD

Study Coordinating Center

Funding Partner

Patient Portal & Genetic Testing Partner

Institutional Review Board
# Data Collection

PROMISE will collect data on the following patient characteristics:

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Medical History/Comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social History</td>
<td>Family Health History</td>
</tr>
<tr>
<td>Histology</td>
<td>Disease State</td>
</tr>
<tr>
<td>Cancer Treatment History</td>
<td>Hospitalizations</td>
</tr>
<tr>
<td>Performance Status</td>
<td>Concomitant Medications</td>
</tr>
<tr>
<td>Progression of Disease (PSA, Radiology)</td>
<td>Routine Lab Values</td>
</tr>
<tr>
<td>Secondary Primary Malignancies</td>
<td>Quality of Life/Patient Reported Outcomes</td>
</tr>
<tr>
<td>Overall Survival</td>
<td>Genomic Sequencing Results</td>
</tr>
</tbody>
</table>
WHAT WILL YOU DO WITH MY DATA? WILL MY INFORMATION BE KEPT CONFIDENTIAL?

Study records that identify you will be kept confidential as required by law. Privacy regulations provide safeguards for privacy, security, and authorized access. More details are provided in the Research Authorization section of this consent form.

We will store your data securely in a scientific database, along with the data from all the other people who take part in the PROMISE study. Your data within the scientific database will be assigned a unique code number. Only the PROMISE study team will have access to the key that links your unique code with your personal information.

Researchers will use the data to learn new information about prostate cancer and possibly make new discoveries or identify new treatments that could help people with prostate cancer. Access to this scientific database will be controlled and limited to researchers that have been approved by the PROMISE study principal investigators. We do not yet know all of the parties who will ask to use the study data in the future.
Prostate Cancer Community Resource

• Every 6 months, participants will receive a newsletter, tailored to their specific mutation(s), including study highlights & information about new treatments or trials that may be available to them.

• Providers will also receive periodic newsletters.

• Long term goal is to incorporate a trial-matching referral service for patients and providers.
Promise.

JOIN US ProstateCancerPromise.org